News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MorphoSys AG Announces Clinical Milestone In Anti-Inflammatory Program


2/17/2014 8:45:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARTINSRIED / MUNICH, Germany, Feb. 17, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial. The HuCAL-derived, fully human antibody will be developed in the therapeutic area of inflammatory diseases.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES